Phenylketonuria (PKU)

Phenylketonuria (PKU) is a rare inherited metabolic disorder in which the body cannot properly break down the amino acid phenylalanine. With early and continuous treatment, individuals with PKU can have normal development and live healthy lives.

  • Cause: Caused by mutations in the PAH gene, leading to deficiency of the enzyme phenylalanine hydroxylase. This results in the buildup of phenylalanine in the blood and brain. It is inherited in an autosomal recessive pattern.

  • Features: Without treatment, high phenylalanine levels can cause intellectual disability, seizures, behavioral problems, eczema, and a musty body odor. Symptoms are prevented with early diagnosis and dietary management.

  • Diagnosis: Detected through newborn screening using a blood test (Guthrie test or tandem mass spectrometry).

  • Treatment: Strict low-phenylalanine diet for life (avoiding high-protein foods), medical formula, and in some cases, medications like sapropterin or pegvaliase to help lower phenylalanine levels.

Active Trials

  • TITLE:

    SPONSOR:

    INDICATION:

    PROTOCOL:

    PHASE:

    DESCRIPTION:

    STATUS:

    RECRUITING PATIENTS:

    RDR LOCATION:

    Inquire About Trial →

Past Trials

  • TITLE: A Phase 1, First-in-Human, Multiple Part, Single Ascending and Multiple Dose Study of JNT-517 in Healthy Participants and in Participants with Phenylketonuria.

    SPONSOR: Jnana Therapeutics, Inc.

    INDICATION: Phenylketonuria (PKU)

    PROTOCOL: JNT517-101

    PHASE: 1/1b

    DESCRIPTION: The goal of Parts A and B of this Phase 1, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of single (SAD) and multiple (MAD) ascending doses of oral JNT-517 in healthy participants. In Part C, the goal is to evaluate the differences in bioavailability between a tablet and suspension formulation of JNT-517 and the food effect in healthy volunteers.

    STATUS: Active

    RECRUITING PATIENTS: No

    RDR LOCATION: Georgia